
NIH
NATIONAL CANCER INSTITUTE
T cell
PD1
pembrolizumab
nivolumab
PDL-1
durvalumab
atezolizumab
IMiDs
lenalidomide
pomalidomide
CTLA4
ipilimumab
tremelimumab
BiTE
blinatumomab
CCR4
mogamulizumab
CD27
varlilumab
IDO-1
INCB024360
Hedgehog
vismodegib
Stem cell signaling
IGF-1R
ganitumab
HER2
trastuzumab
CD30
brentuximab
vedotin
GD2
dinutuximab
GPNMB
glembatumumab
vedotin
Other surface antigen-R
GF
RTK
c-Met
savolitinib
cabozantinib
PDGFR
pazopanib
cediranib
bevacizumab
ziv-aflibercept
VEGF
VEGF-R
CD105
TRC105
Angiopoietins
trebananib
Raf
Ras
dabrafenib
sorafenib
erlotinib
lapatinib
osimertinib
sorafenib
sunitinib
cediranib
pazopanib
cabozantinib
Bcr
Abl
SRC
dasatinib
trametinib
selumetinib
ibrutinib
AZD-8186
copanlisib
PI3K
MEK
Btk
Akt
BER
methoxyamine
ATR
VX-970
PARP
olaparib
veliparib
talazoparib
HDAC
belinostat
entinostat
romidepsin
DNA polymerase
IPdR
DNA-PK
VX-984
Methylation inh.
guadecitabine
CDKi
dinaciclib
palbociclib
Microtubules
eribulin
Aurora kinase A
alisertib
Wee1 kinase
AZD-1775
temsirolimus
TAK-228
mTOR
BAD
BCL-2
navitoclax
XIAP
birinapant
Hsp90
onalespib
Proteasome
bortezomib
DNA replication or repair
RNR
p53
triapine
Protein expression and turnover
Mitosis
Migration/ invasion
Survival/ proliferation
RNR
p53
triapine
MDM2
AMG-232
Apoptosis
Angiogenesis
Immuno-modulation